Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Nitesh D. Kuhadiya, MD, MPH, assistant professor of medicine, has received the Helmsley Charitable Trust Abstract Award from the Endocrine Society for his groundbreaking research that shows significant improvements in glucose control in patients with Type 1 diabetes.
“This is important, as approximately 40 percent of patients with Type 1 diabetes in the United States now have metabolic syndrome, and liraglutide targets three out of the five key features: high blood pressure, diabetes and obesity.”
Kuhadiya’s research — the first randomized, double-blinded, placebo-controlled trial of liraglutide in Type 1 diabetes — shows that the injectable drug benefits Type 1 diabetes patients when used in conjunction with insulin.
http://medicine.buffalo.edu/news_an...4/08/kuhadiya-abstract-award-3989.detail.html
“This is important, as approximately 40 percent of patients with Type 1 diabetes in the United States now have metabolic syndrome, and liraglutide targets three out of the five key features: high blood pressure, diabetes and obesity.”
Kuhadiya’s research — the first randomized, double-blinded, placebo-controlled trial of liraglutide in Type 1 diabetes — shows that the injectable drug benefits Type 1 diabetes patients when used in conjunction with insulin.
http://medicine.buffalo.edu/news_an...4/08/kuhadiya-abstract-award-3989.detail.html